Comparative Pharmacology
Head-to-head clinical analysis: EPICORT versus HYTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPICORT versus HYTONE.
EPICORT vs HYTONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epicort is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects by binding to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
Hydrocortisone (topical) binds to glucocorticoid receptors, activating anti-inflammatory proteins and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
IV: 50 mg every 8 hours over 30 minutes.
Topical: Apply cream or ointment to affected area 2-4 times daily. Limit treatment area to less than 50% of body surface area. Maximum duration: 2 weeks unless directed by physician.
None Documented
None Documented
Terminal half-life is 1.5–2 hours in adults; prolonged to 3–4 hours in severe hepatic impairment
30–60 minutes (terminal elimination half-life; short duration requires frequent dosing)
Renal (70% as unchanged drug and inactive metabolites), biliary/fecal (30%)
Renal (primarily as metabolites; ~25% as unchanged drug) and biliary/fecal
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid